

Genentech

A Member of the Roche Group

600 Massachusetts Ave., NW, Suite 300
Washington, DC 20001
Phone: (202) 296-7272
Fax: (202) 296-7290

17 July 2018

The Honorable Anna G. Eshoo
United States House of Representatives
241 Cannon House Office Building
Washington, DC 20515

The Honorable Susan W. Brooks
United States House of Representatives
1030 Longworth House Office Building
Washington, DC 20515

The Honorable Greg Walden
Chairman
Committee on Energy and Commerce
United States House of Representatives
Rayburn House Office Building
Washington, DC 20515

The Honorable Frank Pallone, Jr.
Ranking Member
Committee on Energy and Commerce
United States House of Representatives
Rayburn House Office Building
Washington, DC 20515

Dear Representatives Eshoo and Brooks, Chairman Walden, and Ranking Member Pallone:

Genentech, Inc. (Genentech) would like to express our strong support for H.R.6378 – *The Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2018*. We applaud your shared leadership and bipartisan efforts to strengthen the nation's public health preparedness and response programs. We are particularly appreciative that H.R.6378 authorizes a specific Pandemic Influenza program at the Biomedical Advanced Research and Development Authority (BARDA) to support research and development activities to enhance a rapid response to pandemic influenza.

As you continue your work toward reauthorization, Genentech welcomes the opportunity to share our relevant experience and provide any needed feedback. Please do not hesitate to contact Dr. Andrew Womack, Director, Federal Government Affairs, at womack.andrew@gene.com or (202) 957-8634 if you have any questions or requests.

Sincerely,



David Burt
Senior Director, Federal Government Affairs
Genentech, Inc.